C0014644||EBV
C1101610||MicroRNA BART16
C2610474||Type I IFN Signaling
C0021743||Type I IFNs
C1155328||antiviral defense
C1155328||antiviral activities
C0332479||shaping
C1749719||adaptive immune response
C0042776||Viruses
C1819430||IFN production
C0021054||downstream mediators
C3714514||infection
C0014644||EBV
C0021345||infectious mononucleosis
C0006826||malignant tumors
C1654934||immune-evasion
C0033684||proteins
C0678209||adaptive
C0020962||immune systems
C0033684||proteins
C0042776||virus
C1101610||microRNAs
C0014644||EBV
C1101610||miR-BART16
C1654934||immune-evasion
C2610474||type I IFN signaling pathway
C1101610||miR-BART16
C0256079||CREB-binding protein
C1336776||transcriptional coactivator
C1512827||IFN signaling
C0256079||CREB-binding protein
C0013081||downregulation
C2699839||EBV-transformed B cells
C1333789||gastric carcinoma cells
C1101610||miR-BART16
C0021747||IFN
C0038337||stimulated
C0017337||genes
C0002199||IFN-α
C0038337||stimulation
C0003392||antiproliferative
C0002199||IFN-α
C0439663||infected
C0004561||BL cells
C0021743||type I IFN
C1155328||antiviral response
C1101610||miR-BART16
C0014644||EBV
C3714514||infection
C0042774||viral replication